chr13-23335561-C-G
Variant names: 
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM2
The NM_014363.6(SACS):c.8315G>C(p.Gly2772Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000545 in 1,613,640 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
 Genomes: 𝑓 0.000039   (  0   hom.,  cov: 33) 
 Exomes 𝑓:  0.000056   (  0   hom.  ) 
Consequence
 SACS
NM_014363.6 missense
NM_014363.6 missense
Scores
 13
 6
Clinical Significance
Conservation
 PhyloP100:  7.50  
Publications
2 publications found 
Genes affected
 SACS  (HGNC:10519):  (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013] 
SACS Gene-Disease associations (from GenCC):
- Charlevoix-Saguenay spastic ataxiaInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Myriad Women’s Health
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage; 
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.0000394  AC: 6AN: 152130Hom.:  0  Cov.: 33 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
6
AN: 
152130
Hom.: 
Cov.: 
33
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.0000518  AC: 13AN: 250940 AF XY:  0.0000737   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
13
AN: 
250940
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.0000561  AC: 82AN: 1461510Hom.:  0  Cov.: 37 AF XY:  0.0000591  AC XY: 43AN XY: 727054 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
82
AN: 
1461510
Hom.: 
Cov.: 
37
 AF XY: 
AC XY: 
43
AN XY: 
727054
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
33470
American (AMR) 
 AF: 
AC: 
0
AN: 
44712
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
1
AN: 
26128
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
39694
South Asian (SAS) 
 AF: 
AC: 
1
AN: 
86254
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
53204
Middle Eastern (MID) 
 AF: 
AC: 
2
AN: 
5768
European-Non Finnish (NFE) 
 AF: 
AC: 
73
AN: 
1111898
Other (OTH) 
 AF: 
AC: 
5
AN: 
60382
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.489 
Heterozygous variant carriers
 0 
 7 
 13 
 20 
 26 
 33 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Variant carriers
 0 
 4 
 8 
 12 
 16 
 20 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.0000394  AC: 6AN: 152130Hom.:  0  Cov.: 33 AF XY:  0.0000269  AC XY: 2AN XY: 74318 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
6
AN: 
152130
Hom.: 
Cov.: 
33
 AF XY: 
AC XY: 
2
AN XY: 
74318
show subpopulations 
African (AFR) 
 AF: 
AC: 
0
AN: 
41434
American (AMR) 
 AF: 
AC: 
0
AN: 
15268
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3468
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5188
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
4832
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10616
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
316
European-Non Finnish (NFE) 
 AF: 
AC: 
6
AN: 
68016
Other (OTH) 
 AF: 
AC: 
0
AN: 
2080
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.500 
Heterozygous variant carriers
 0 
 1 
 2 
 2 
 3 
 4 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Variant carriers
 0 
 2 
 4 
 6 
 8 
 10 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
ExAC 
 AF: 
AC: 
6
EpiCase 
 AF: 
EpiControl 
 AF: 
ClinVar
Significance: Conflicting classifications of pathogenicity 
Submissions summary: Pathogenic:1Uncertain:5Benign:1 
Revision: criteria provided, conflicting classifications
LINK: link 
Submissions by phenotype
Charlevoix-Saguenay spastic ataxia    Pathogenic:1Uncertain:3 
Nov 12, 2021
Revvity Omics, Revvity
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Oct 31, 2018
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Jan 01, 2022
PROSPAX: an integrated multimodal progression chart in spastic ataxias, Center for Neurology; Hertie-Institute for Clinical Brain Research
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:research
- -
Sep 05, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not specified    Uncertain:1 
Oct 24, 2016
Athena Diagnostics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not provided    Uncertain:1 
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Spastic paraplegia    Benign:1 
Jan 03, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 AlphaMissense 
 Benign 
 BayesDel_addAF 
 Uncertain 
D 
 BayesDel_noAF 
 Uncertain 
 DANN 
 Uncertain 
 DEOGEN2 
 Benign 
.;T 
 Eigen 
 Uncertain 
 Eigen_PC 
 Uncertain 
 FATHMM_MKL 
 Uncertain 
D 
 LIST_S2 
 Uncertain 
D;D 
 M_CAP 
 Benign 
D 
 MetaRNN 
 Uncertain 
D;D 
 MetaSVM 
 Uncertain 
T 
 MutationAssessor 
 Uncertain 
.;M 
 PhyloP100 
 PrimateAI 
 Uncertain 
T 
 PROVEAN 
 Benign 
N;N 
 REVEL 
 Uncertain 
 Sift 
 Benign 
T;T 
 Sift4G 
 Uncertain 
D;D 
 Polyphen 
 0.97 
.;D 
 Vest4 
 MutPred 
 0.36 
.;Gain of helix (P = 0.027);
 MVP 
 ClinPred 
D 
 GERP RS 
 Varity_R 
 gMVP 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.